Sep 14 2012
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT)
reported today that the first patient has been enrolled and dosing has
been initiated in cohort 2 of its clinical trial with SNS01-T in
multiple myeloma. SNS01-T was well tolerated and met the criteria for
Stable Disease in 2 of the 3 evaluable patients that comprised cohort 1.
"We were very pleased that the first group, infused with the lowest dose
of SNS01-T provided encouraging results including two patients with
stable disease of which one patient remained stable at 4 weeks and
progressed at 8 weeks after the end of the dosing period," stated Leslie
J. Browne, Ph.D., President and CEO of Senesco. "Now that cohort 2 is
underway and there are three clinical sites recruiting patients we hope
to be able to disclose results on the four-fold higher dose of
approximately 4 mg per patient around the end of 2012."
The study is an open-label, multiple-dose, dose-escalation study, which
is evaluating the safety and tolerability of SNS01-T when administered
by intravenous infusion to approximately 15 relapsed or refractory
multiple myeloma patients. Patients are dosed twice-weekly for 6 weeks
followed by an observation period. The first group of patients received
0.0125 mg/kg, approximately 1 mg per patient, by intravenous infusion.
The planned dose levels for the second, third and fourth groups are
0.05, 0.2 and 0.375 mg/kg, respectively.
While the primary objective of this study is to evaluate safety and
tolerability, the effect of SNS01-T on tumor response and time to
relapse or progression will be assessed using multiple well-established
metrics including measurement of monoclonal protein.
Source: Senesco Technologies, Inc.
Navigating the complexities of controlled release drug formulations